英夫利昔单抗治疗大动脉炎：一种安全的替代疗法？
Infliximab in Takayasu arteritis: a safe alternative?
作者信息
Karageorgaki Zaharenia Th, Mavragani Clio P, Papathanasiou Matthilde A, Skopouli Fotini N
机构信息
Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece.
出版信息
Clin Rheumatol. 2007 Jun;26(6):984-7. doi: 10.1007/s10067-006-0227-0. Epub 2006 Apr 22.
OBJECTIVE
To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-alpha, in the treatment of Takayasu arteritis.
MATERIALS AND METHODS
We used infliximab at an initial dose of 3 mg/kg i.v. at weeks 0, 2, 6, and 8 thereafter in combination with methotrexate or azathioprine, to treat four patients with Takayasu arteritis.
RESULTS
Three out of four patients responded to infliximab treatment, while two of them retained the response during a two-year follow up. A higher dose regimen (5 mg/kg), however, was eventually warranted for two of the responders. No major side effects were noted.
CONCLUSIONS
Infliximab might be an effective and safe alternative for patients with Takayasu arteritis.
目的
测试英夫利昔单抗（一种抗肿瘤坏死因子-α的嵌合单克隆抗体）治疗大动脉炎的疗效。
材料与方法
我们使用英夫利昔单抗，初始剂量为3mg/kg静脉注射，在第0、2、6和8周给药，此后与甲氨蝶呤或硫唑嘌呤联合使用，治疗4例大动脉炎患者。
结果
4例患者中有3例对英夫利昔单抗治疗有反应，其中2例在两年随访期间维持反应。然而，最终有2例有反应者需要更高剂量方案（5mg/kg）。未观察到严重副作用。
结论
英夫利昔单抗可能是大动脉炎患者一种有效且安全的替代治疗药物。
Zotero 插件